AIM2 Inflammasome Modulation Therapy targets the AIM2 (Absent in Melanoma 2) inflammasome pathway to reduce chronic neuroinflammation and prevent neuronal cell death in Alzheimer's disease, Parkinson's disease, and ALS. This therapy represents a novel approach targeting DNA-sensing innate immune pathways that are distinct from the well-characterized NLRP3 inflammasome.
| Disease | Score (1-10) | Rationale |
|---|---|---|
| Alzheimer's Disease | 9 | Upregulated in AD brain, particularly in microglia surrounding amyloid plaques; promotes chronic neuroinflammation |
| Parkinson's Disease | 8 | Contributes to dopaminergic neuron death via inflammasome-mediated pathways |
| ALS | 8 | Detected in motor neuron degeneration; contributes to neuroinflammation |
| FTD | 6 | Inflammasome activation in TDP-43 pathology |
| Aging | 8 | Age-related increase in cytosolic DNA accumulation activates AIM2 |
Total Score: 77/100
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8 | AIM2 is distinct from NLRP3, representing DNA-sensing pathway not yet targeted in neurodegeneration clinical trials |
| Mechanistic Rationale | 9 | Strong evidence: AIM2 upregulated in AD/PD/ALS brain; genetic knockdown reduces pathology in animal models |
| Root-Cause Coverage | 8 | Addresses upstream inflammatory trigger (cytosolic DNA accumulation) rather than downstream symptoms |
| Delivery Feasibility | 7 | CNS-penetrant small molecules possible; ASC inhibitors under development |
| Safety Plausibility | 7 | Physiological AIM2 function is protective against pathogens; partial inhibition may preserve immunity |
| Combinability | 9 | Synergistic with NLRP3 inhibitors (hybrid inflammasomes exist), TREM2 modulators, anti-amyloid approaches |
| Biomarker Availability | 8 | CSF IL-18, ASC specks in blood, PET ligands for neuroinflammation |
| De-risking Path | 7 | AIM2 inhibitors in oncology pipeline provide safety data; proof-of-concept in neurodegeneration models |
| Multi-disease Potential | 9 | Strong rationale across AD, PD, ALS, FTD, and aging |
| Patient Impact | 7 | Addresses chronic neuroinflammation affecting millions of patients |
| Risk | Mitigation |
|---|---|
| Off-target effects on immunity | Partial inhibition strategies, biomarker monitoring |
| Insufficient CNS penetration | Dedicated CNS optimization, intranasal delivery |
| Redundancy with other inflammasomes | Dual AIM2/NLRP3 targeting |